Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.
The share count has stayed roughly flat over this period — little dilution or buyback activity.
Diluted shares outstanding: 44.5M (2021) → 44.5M (2025)
Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.
Negative ROIC means the business is losing money on every dollar invested in it.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Single-digit earnings growth — steady but not exciting.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
P/E over 35. The market is pricing in heavy, sustained growth.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
Modest yield. The bulk of any return needs to come from price appreciation.
Full breakdown available with your free trial
See every metric, trend, and what it means for this stock.
